EcoDrugPlus

Lysyl Oxidase Homolog 2a-Like

Ensembl ID : ENSNFUG00015011838
Gene Symbol: LOC107385502
3 Cross references
209 Possible Orthologues:

Lysyl Oxidase-Like 2b

Ensembl ID : ENSNFUG00015013900
Gene Symbol: LOXL2B
1 Cross references
203 Possible Orthologues:

Lysyl Oxidase-Like 2b

Ensembl ID : ENSNFUG00015009232
Gene Symbol: LOXL2B
1 Cross references
206 Possible Orthologues:

Macrophage Colony-Stimulating Factor 1 Receptor 1-Like

Ensembl ID : ENSNFUG00015013427
Gene Symbol: LOC107375663
3 Cross references
63 Possible Orthologues:

Macrophage Migration Inhibitory Factor

Ensembl ID : ENSNFUG00015008911
Gene Symbol: MIF
3 Cross references
229 Possible Orthologues:

Macrophage-Stimulating Protein Receptor-Like

Ensembl ID : ENSNFUG00015010867
Gene Symbol: LOC107385200
3 Cross references
188 Possible Orthologues:

Matrix Metallopeptidase 13a

Ensembl ID : ENSNFUG00015016769
Gene Symbol: MMP13A
1 Cross references
283 Possible Orthologues:

Matrix Metallopeptidase 14

Ensembl ID : ENSNFUG00015000298
Gene Symbol: MMP14
3 Cross references
198 Possible Orthologues:

Matrix Metallopeptidase 2

Ensembl ID : ENSNFUG00015021127
Gene Symbol: MMP2
1 Cross references
209 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSNFUG00015022858
Gene Symbol: MMP9
1 Cross references
215 Possible Orthologues:

Matrix Metalloproteinase-14-Like

Ensembl ID : ENSNFUG00015007461
Gene Symbol: LOC107384247
3 Cross references
196 Possible Orthologues:

Matrix Metalloproteinase-20-Like

Ensembl ID : ENSNFUG00015005168
Gene Symbol: LOC107380716
2 Cross references
163 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).